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Background: A Phase II study (NCT00494234) showed that the oral PARP inhibitor olaparib (400 mg bid; capsules) exerts antitumour activity in BC pts with a gBRCAm (Tutt et al Lancet 2010) . Three Phase III trials of olaparib monotherapy have been initiated in BC pts with a gBRCAm: OlympiA (NCT02032823), Neo-Olympia (D081EC00005), OlympiAD (NCT02000622). Trial design: Trial designs are summarized in the Table. For each trial, eligible pts will have a BRCAm and will undergo gBRCAm testing (Myriad Integrated BRACAnalysis®) as part of the trial. For OlympiA, pts must be at high risk of recurrence and have completed local treatment and either neoadjuvant (without pCR) or adjuvant chemotherapy. For Neo-Olympia, pts can have operable, locally advanced or inflammatory BC, must have a tumour >2 cm by clinical exam (or >1 cm by radiological exam) and must have completed four cycles of anthracycline plus carboplatin without disease progression. For OlympiAD, pts can have TNBC or HER2-negative BC, and must have received prior anthracycline and taxane in the adjuvant or metastatic setting, and ≤2 chemotherapy lines for mBC. In OlympiA, pts will receive treatment for up to 12 months; efficacy will be assessed q 3 months up to 24 months, then q 6 months up to 60 months, then q 12 months. In Neo-Olympia, pts will receive treatment for 12 wks pre-surgery and then for 40 wks post-surgery. In OlympiAD, PFS will be assessed by RECIST v1.1; radiologic exams will be performed at baseline, q 6 wks up to 6 months, and then q 12 wks until disease progression. In OlympiA and OlympiAD, IDFS and PFS, respectively, will be analyzed using stratified log-rank tests; for Neo-Olympia, pCR rate will be analyzed with an adjusted logistic regression model. Primary analyses will be undertaken after 330 IDFS events (OlympiA), surgery (Neo-Olympia) and 230 PFS events (OlympiAD). *Curative-intent surgery to be performed after 12 wks, after which pts will receive olaparib 300 mg bid (Arm A), placebo (Arm B), or either weekly paclitaxel 80 mg/m 2 for
